TGFβ promotes YAP‐dependent AXL induction in mesenchymal‐type lung cancer cells
Open Access
- 18 November 2020
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 15 (2) , 679-696
Abstract
The acquisition of chemoresistance remains a major cause of cancer mortality due to the limited accessibility of targeted or immune therapies. However, given that severe alterations of molecular features during epithelial‐to‐mesenchymal transition (EMT) lead to acquired chemoresistance, emerging studies have focused on identifying targetable drivers associated with acquired chemoresistance. Particularly, AXL, a key receptor tyrosine kinase that confers resistance against targets and chemotherapeutics, is highly expressed in mesenchymal cancer cells. However, the underlying mechanism of AXL induction in mesenchymal cancer cells is poorly understood. Our study revealed that the YAP signature, which was highly enriched in mesenchymal‐type lung cancer, was closely correlated to AXL expression in 181 lung cancer cell lines. Moreover, using isogenic lung cancer cell pairs, we also found that doxorubicin treatment induced YAP nuclear translocation in mesenchymal‐type lung cancer cells to induce AXL expression. Additionally, the concurrent activation of TGFβ signaling coordinated YAP‐dependent AXL expression through SMAD4. These data suggest that crosstalk between YAP and the TGFβ/SMAD axis upon treatment with chemotherapeutics might be a promising target to improve chemosensitivity in mesenchymal‐type lung cancer.Keywords
Funding Information
- National Research Foundation of Korea (2020R1A2C2005914, 2017M3C9A5028691)
- Norwegian Research Council
This publication has 57 references indexed in Scilit:
- Connectivity map-based drug repositioning of bortezomib to reverse the metastatic effect of GALNT14 in lung cancerOncogene, 2020
- In silico drug repositioning: from large-scale transcriptome data to therapeuticsArchives of Pharmacal Research, 2019
- Large-scale pharmacogenomics based drug discovery for ITGB3 dependent chemoresistance in mesenchymal lung cancerMolecular Cancer, 2018
- BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancerCancer Letters, 2017
- Drugging the 'undruggable' cancer targetsNature Reviews Cancer, 2017
- Chronic TGFβ stimulation promotes the metastatic potential of lung cancer cells by Snail protein stabilization through integrin β3-Akt-GSK3β signalingOncotarget, 2016
- Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistanceNature, 2015
- An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibitionNature Cell Biology, 2014
- Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial‐to‐mesenchymal transitionInternational Journal of Cancer, 2013
- Chemotherapy, chemoresistance and the changing treatment landscape for NSCLCLung Cancer, 2011